MedTrace Logo

Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden

NCT03778333 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2023-06-01

No results posted yet for this study

Summary

To assess the safety of a single dose of IV infusion of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) in Multiple Sclerosis (MS) with progressive disease status.

Conditions

Interventions

BIOLOGICAL

Autologous mesenchymal stem cells

IV therapy with autologous bone-marrow derived mesenchymal stem cells

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-01
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03778333 on ClinicalTrials.gov